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ABSTRACT
In the United States and Europe, gastroesophageal 
reflux (GER) is receiving attention as a potential cause 
of bronchial asthma. Few Japanese case reports have 
described this relationship. Therefore, we investigated 
the effect of omeprazole and cisapride on pulmonary 
function tests, blood gases and home peak expiratory 
flow rates (PEFR) in six Japanese outpatients with 
asthma and proven GER. After 8 weeks of treatment,
reflux esophagitis had improved in all patients. 
However, the parameters of pulmonary function 
showed no change other than a significant post-
treatment increase in home PEFR (4.4-27.7%) in three 
patients. These results suggest that anti-reflux 
(omeprazole and cisapride) treatment will produce 
small improvements in the PEFR in some Japanese 
asthmatics with GER.
Key words: bronchial asthma, cisapride, 
gastroesophageal reflux, Japanese, omeprazole, 
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INTRODUCTION
In the United States and Europe, gastroesophageal reflux 
(GER) has been demonstrated in approximately 40% of 
asthma patients.1,2 However, in Japan, few case reports
have provided details regarding the relationship between 
these two {actors.3 We have diagnosed GER in six of 21 
perennial asthma patients (29%) via fiberoptic
esophagoscopy.4 We have also reported that many 
patients with asthma and concurrent GER have not been 
diagnosed. The body mass index (BMI) and gastric 
acid pH, which are closely related to the risk of GER,5
differ among races.6,7 We therefore considered that 
investigation of the relationship between broncho-
constriction and GER in Japanese asthma patients was 
justified.
 There have been some reports of pulmonary function 
data and peak expiratory flow rates (PEFR) obtained 
during histamine H2 receptor antagonist treatment in 
asthma patients with GER, but these results have 
been controversial.8,9 Histamine H2 receptor antagonists,
particularly cimetidine, alter the clearance of 
theophylline,10-13 which may have been responsible for 
the differences in these results.
 Omeprazole and cisapride have been used in the 
treatment of reflux esophagitis. Omeprazole has been 
shown to give reliable and effective 24h control of acid 
secretion. This gives rapid symptom relief and healing 
in patients with reflux esophagitis.14 Cisapride enhances 
gastrointestinal motility by increasing the release of 
acetylcholine via the 5-hydroxytryptamine receptor in
humans.15 These drugs have not been known to influence 
the serum theophylline concentration. The present paper 
reports the effects of reflux esophagitis therapy, consisting 
of omeprazole and cisapride (not histamine H2 receptor 
antagonists), on pulmonary function tests, blood gases 
and home PEFR in Japanese asthma patients treated as 
outpatients.
METHODS
Subjects
Potential subjects included patients referred to the 
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Kakizaki Hospital and diagnosed with bronchial asthma 
and reflux esophagitis between January and December 
1993. Of these patients, those who periodically recorded 
their PEFR in the early morning and evening were 
selected for this study. All patients were non-smokers 
with symptoms of reflux. Bronchial asthma was 
diagnosed by a history of episodic dyspnea with wheezing
and reversible increases in the forced expiratory volume 
in 1s (FEV1.0) of more than 20%, either spontaneously or 
after medication.16 No subject with bronchial asthma had 
had any attacks during the 6 week period prior to the 
study. In addition, no subject had a history of respiratory 
tract infection for 6 weeks prior to the study. Asthma
severity was classified according to the Global Strategy 
for Asthma Management and Prevention.17 Informed 
consent was obtained from each subject prior to the start 
of the study, which was approved by the Institute's 
Committee on Clinical Research.
Diagnostic methods
Each diagnosis of esophagitis, confirmed by 
esophagoscopy and histopathologic examination of 
esophagoscopic biopsy findings, was evaluated by two 
or more gastroenterologists. Reflux esophagitis was 
classified according to the criteria of Savary and Miller.18
 The forced vital capacity (FVC), FEY1.0, V25/body height 
(V25/Ht) and arterial blood gas values (oxygen tension 
(PaO2), carbon dioxide tension (PaCO2), alveolar-
arterial oxygen tension gradient (A-aDO2)) were also 
measured in asthma patients with evidence of reflux 
esophagitis.
 Pulmonary function was determined using a hot-wire 
flow meter (Autospiro AS-7; Minato Corp., Tokyo, 
Japan). Blood gas analysis was performed as follows: 
after patients had rested in a supine position for longer 
than 15min, blood samples were obtained from the 
brachial artery and were heparinized prior to injection
into an automatic pH blood gas analyzer (Ciba Corning 
278; Ciba-Corning Diagnostic Corp., Tokyo, Japan). 
The PaO2 and PaCO2 were measured in each sample. 
According to the method of Comroe,19 the ideal alveolar
oxygen tension was calculated from the PaCO2. The 
A-aDO2 was calculated by subtracting PaO2 from the ideal 
alveolar oxygen tension. 
 Peak expiratory flow rates from the early morning and
evening, which had been periodically recorded in asthma 
patients' diaries for 2 weeks prior to the study, were 
obtained. The patients were provided with a Wright mini-
peak flow meter (Clement Clark International Ltd,
Harlow, UK). Three peak flow readings were taken at 
three time points and the highest value was entered on a 
diary card. Patients recorded their PEFR twice a day 
during omeprazole and cisapride treatment.
  Patients were also given an 8 week supply of 
omeprazole (20mg/day) and cisapride (7.5mg/day) 
tablets. Patients continued their conventional asthma 
therapy. After 8 weeks of treatment, the FVC, FEY1,0, 
V25/Ht,PaO2, and A-aDO2 were reassessed and repeat 
esophagoscopy was performed.
Statistical analysis
Pre- and post-treatment FVC, FEY1,0, V25/Ht, PaO2, and 
A-aDO2 values were compared along with weekly
summed PEFR. Results are expressed as the mean±SD.
Statistical analysis was performed using the Wilcoxon 
rank sum test. A P value of <0.05 was considered 
statistically significant.
RESULTS
All six patients who entered the study, completed the trial 
period. The subjects included four men and two women 
with a mean age of 53 years (range 33-61 years). All 
suffered perennial asthma attacks. Four patients had 
atopic disease and two had non-atopic disease. All 
patients were classified with moderate asthma (Table 1).
They were managed with oral theophylline (500-700 
mg/day), an inhaled steroid (beclomethasone dipro-
pinnate,400-800μg/day) and a short-acting inhaled
(32-adrenoceptor agonist (procaterol hydrochloride;
10 60μg/day). Three patients took an oral β2-adrener-
gic drug (procaterol hydrochloride; 50-100μg/day;
Table 2).
There was no difference in the frequency of the use 
of in aled bronchodilators or other asthmatic therapy 
b twee  pre- and post-treatment periods. Asthma 
symptoms in all six patients, such as cough, chest 
tightness, wheezing and dyspnea, did not worsen.
 Pre- and post-treatment FVC, FEV1,0, V25/Ht and 
blood gas values did not differ significantly (Table 3). 
Classification of reflux esophagitis according to the 
criteria of Savary and Miller18 showed that four patients 
had stage I disease and two had stage II disease. All 
c ses of reflux esophagitis improved after treatment.
Figure 1 shows the early morning and evening PEFR 
values obtained during the 8 weeks of omeprazole and 
cisapride treatment and during the preceding 2 week 
interval. Peak expiratory flow rates performed at similar
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Table 1. Subject characteristics
Table 2. Subject characteristics
Table 3. Pulmonary function parameters before and after omeprazole and cisapride treatment in six asthma patients with reflux 
esophagitis
Fig. 1 Peak expiratory flow rates (PEER) in the early morning
(●) and evening (○) before ond after treatment With
omeprazole and cisapride. Pre-and post-treatment PEFR did
not differ significantly.Vaues ore presented as the mean±SD.
times of the day did not differ significantly between pre-
and post-treatment. However, three of six patients (patients 
SS, AY, MM) showed significantly increased PEFR at both 
times of the day after 8 weeks of treatment. The increases
in early morning and evening PEFR in the three patients 
were calculated as (PEFR after 8 weeks of treatment)
-(PEER 2 weeks prior to the study)×100/(PEER 2 weeks
prior to the study) and were found to be 6.5, 27.7 and 
24.3% and 4.4, 18.5 and 17.6%, respectively (Fig. 2a). 
Two of six patients (patients YK and MK) showed signifi-
cantly decreased PEFR and one (patient OH) showed no 
change in the PEFR at either time of the day (Fig. 2b).
DISCUSSION
Suffering from reflux symptoms is an essential feature of 
GER. Jenkinson et al.20 have reported that both reflux 
symptoms and ssociated endoscopic findings could be
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Fig. 2 (a) Three representative pafients showed improved morning (●) and evening (○) peak expiratory flow rates (PEFR) after
treatment with omeprazole and cisapride. (b) Two patients revealed decreased PEFR and one patient showed unchanged PEFR at
both times of the day after anti-reflux treatment. *P<0.05, **P<0.01, ***P<0.005.
detected in their patients with GER. In the present study of 
Japanese asthmatics with reflux esophagitis indicative of 
GER, there were no significant changes in FVC, FEV,a, 
V25/Ht, PEFR, PaO2 or A-aDO2 during pre- and post-
omeprazole and -cisapride treatment followed by the
usual asthma therapy. However, reflux esophagitis 
improved in all patients. Three of six patients showed a 
significant increase in home PEFR. 
 Goodall et al.8 have performed a double-blind cross-
over study comparing asthma symptoms, pulmonary 
function test data and home PEFR values in 20 patients
with asthma and GER receiving cimetidine therapy 
or a placebo. Asthma symptoms and PEFR in patients 
treated with cimetidine for 6 weeks improved significantly 
in comparison with placebo. However, other pulmonary 
func ion data between cimetidine and placebo treatment
groups did not differ significantly. Ekstrom et al.9 
also compared 4 weeks of ranitidine therapy with 4 
weeks of placebo in 48 asthma patients. Respiratory and 
eflux symptoms decreased significantly with ranitidine 
therapy, but pulmonary function data, home PEFR values 
and bronchial sensitivity did not change significantly.
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 According to these two reports, the effects of histamine 
H2 receptor antagonists on asthma symptoms and 
pulmonary function data are similar, but improvement in 
home PEFR is controversial. Histamine H2 receptor 
antagonists, particularly cimetidine, alter theophylline 
clearance, causing an increase in the serum theophylline 
concentration.10-13 Goodall et al.8 did not mention
whether their subjects were taking theophylline. If their 
subjects had been taking theophylline during cimetidine 
treatment, the serum theophylline concentration may 
have increased, influencing the PEFR. In addition, 
Ekstrom et al.9 have reported that 26 of their 48 subjects
were taking theophylline. In the present study, omepra-
zole and cisapride treatment were used instead of a 
histamine H2 receptor antagonist, thus avoiding the 
influence of potential changes in the serum theophylline 
concentration induced by cimetidine.
 There has been no report of omeprazole or cisapride 
influencing the serum theophylline concentration, directly 
affecting the bronchomotor tone or inducing broncho-
dilation. In four of six patients in the present study, the 
serum theophylline concentration was measured before 
and after omeprazole and cisapride treatment and was
not different before and after treatment (10.9±4.7 vs
9.2±5.6μg/mL, respectively). Therefore, we conclude
that omeprazole and cisapride treatment effectively 
increases gastric acid pH and decreases GER without 
influencing theophylline concentration. The result of no 
significant difference between pre- and post-treatment 
PEFR was consistent with the results of the study of 
Ekstrom et al.9 Our study subjects were stable asthmatics 
without symptoms during the preceding 6 weeks. The
mean age of the patients in the study of Ekstrom et al.9 
was 59 years and their mean FEV,.a was 2.26 L. Thus, the 
degree of bronchoconstriction in the patients in the study 
of Ekstrom may have been similar to that in our subjects 
at the onset of the study. In contrast, different degrees of 
bronchoconstriction at the onset of the study (an FEY, o
of 62% recorded by Goodall et al.8 compared with an 
FEY, o/FVC (2.33/3.40) of 69% in the present study) may 
have accounted for the different results between our study 
and that of Goodall et al.
 In addition, gastric acid pH and degrees of obesity, 
which are both related to GER, differ among races.6,7 
Therefore, we believe that differences among the subjects 
studied and the therapeutic agents used (H2 receptor
antagonists vs omeprazole and cisapride) between these 
three studies may be related to the different results 
observed.
 With regard to the etiology of GER-induced asthma 
attacks, two hypotheses have been proposed. One 
involves the microaspiration of hydrochloric acid into 
the lungs due to GER.21-23 The other involves broncho-
constriction caused by vagal reflexes from the 
esophagus, trachea and bronchi, enhanced by 
stimulation of the esophageal mucosa due to 
hydrochloric acid.24,25 It is difficult to draw definitive 
conclusions regarding the mechanisms underlying GER-
induced asthma attacks. Previously, we have reported
three patients with a GER-induced cough diagnosed by 
bronchial biopsy as having chronic airway inflammation
accompanied by a lymphocytic infiltration.26,27 Therefore, 
we speculate that repeat tracheobronchial micro-
aspiration of reflux gastric acid or vagally mediated reflux
may cause chronic inflammatory damage to the 
bronchial mucosa and resultant asthmatic attacks.
In the present study the peak flow improvements were
minor and probably of little clinical significance in our
Japanese asthma patients with reflux esophagitis. Our 
study sample size was small, therefore, no definite con-
clusions can be drawn. In Japan, further study is needed 
to investigate the mechanism of GER-induced asthma.
REFERENCES
1 Mays EE. Intrinsic asthma in adults. Association with 
  gastroesophageal reflux. JAMA 1976; 236: 2626-8. 
2 Sontag SJ, Schnell TG, Miller TQ et al. Prevalence of 
  oesophagitis in asthmatics. Gut 1992; 33: 872-6.
3 Fujimori K, Suzuki E, Arakawa M. A case of bronchial 
  asthma associated with reflux esophagitis, whose peak 
  expiratory flow rate improved with omeprazole and 
  cisapride. Jpn. J. Thoracic Dis. 1994; 32: 1088-93 (in 
  Japanese with English abstract).
4 Fujimori K, Hayatsu K, Suzuki E, Arakawa M. Relationship 
  between upper gastrointestinal diseases and perennial 
  asthma. Jpn. J. Thoracic Dis. 1994; 32 (Suppl.): 282 (in 
  Japanese).
5 Mercer CD, Wren SF, DaCosta LR, Beck IT. Lower 
  esophageal sphincter pressure and gastroesophageal 
  pressure gradients in excessively obese patients. J. Med. 
  1987; 18: 135-46.
6 Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of 
  upper body obesity. Diabetes 1993; 42: 537-43. 
7 Feldman M, Richardson CT, Lam SK, Samloff IM. 
  Comparison of gastric acid secretion rates and serum 
  pepsinogen I and II concentrations in occidental and 
  oriental duodenal ulcer patients. Gastroenterology 1988; 
  95: 630-5.
8 Goodall RJR, Earis JE, Cooper DN, Bernstein A, Temple 
  JG. Relationship between asthma and gastro-oesophageal 
  reflux. Thorax 1981; 36: 116-21.
172 K FUJIMORI ET AL.
9 Ekstrom T, Lindgren BR, Tibbling L. Effects of ranitidine 
  treatment on patients with asthma and a history of gastro-
  oesophageal reflux: A double blind crossover study. Thorax 
  1989; 44: 19-23.
10 Reitberg DP, Bernhard H, Schentag JJ. Alteration of 
   theophylline clearance and half-life by cimetidine in 
   normal volunteers. Ann. Intern. Med. 1981; 95: 582-5. 
11 Fernandez E, Melewicz FM. Ranitidine and theophylline. 
  Ann. Intern. Med. 1985; 100: 459 (Letter).
12 Gardner ME, Sikorski GW. Ranitidine and theophylline. 
  Ann. Intern. Med. 1985;102: 559 (Letter). 
13 Kelly HW, Powell JR, Donohue JF Ranitidine at very large 
   doses does not inhibit theophylline elimination. Clin. 
   Pharmacol. Ther. 1986; 39: 577-81.
14 Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole 
   or ranitidine in the treatment of reflux esophagitis. Results 
   of a double-blind, randomized Scandinavian multicenter 
   study. Scand. J. Gastroenterol. 1988; 23: 625-32. 
15 Stacher G, Steinringer H, Schneider C, Winklehner S, 
   Mittelbach G, Gaupmann G. Effects of cisapride on
   jejunal motor activity in fasting healthy humans. 
   Gastroenterology 1986; 90: 1210-16. 
16 American Thoracic Society. Standards for the diagnosis 
   and care of patients with chronic obstructive pulmonary 
   disease (COPD) and asthma. Am. Rev. Respir. Dis. 1986 
   135: 225-44.
17 Global Initiative for Asthma. Global Strategy for Asthma 
   Management and Prevention. NHLBI/WHO Workshop 
   Report, March 1993. NIH, NHLBI,1995. 
18 Savary M, Miller G. The Esophagus. In: Gassmann AG 
   (ed.). Handbook and Atlas of Fndoscopy. Switzerland,
   Solothurn,1978. 
19 Comroe JH, Forster RE, DuBois AB, Briscoe WA, Carlsen E. 
   The Lung, 2nd edn. Chicago: Year Book Medical 
   Publishers, 1962.
20 Jenkinson LR, Norris TL, Watson A. Symptoms and 
   endoscopic findings: Can they predict abnormal nocturnal 
   acid gastro-oesophageal reflux? Ann. R. Coll. Surg. 1989; 
   71: 117-19.
21 Reich SB, Earley WC, Ravin TH, Goodman M, Spector S, 
   Stein MR. Evaluation of gastropulmonary aspiration by a 
   radioactive technique: Concise communication. J. Nucl. 
   Med. 1977; 18: 1079-81.
22 Crausaz FM, Favez G. Aspiration of solid food particles 
   into lungs of patients with gastroesophageal reflux and 
   chronic bronchial disease. Chest 1988; 93: 376-8.
23 Boyle JT, Tuchman DN, Altschuler SM, Nixon TE, Pack AI, 
   Cohen S. Mechanisms for the association of gastro-
   esophageal reflux and bronchospasm. Am. Rev. Respir. 
   Dis. 1985; 131 (Suppl.): 516-20.
24 Mansfield LE, Hameister HH, Spaulding HS, Smith NJ, 
   Glab N. The role of the vagus nerve in airway narrowing 
   caused by intraesophageal hydrochloric acid provocation 
   and esophageal distension. Ann. Allergy 1981; 47: 
   431-4.
25 Herve P, Denjean A, Jian R, Simonneau G, Duroux P 
   Intraesophageal perfusion of acid increases the 
   bronchomotor response to methacholine and to isocapnic 
   hyperventilation in asthmatic subjects. Am. Rev. Respir. Dis. 
   1986; 134: 986-9.
26 Fujimori K, Suzuki E, Arakawa M. A case of chronic 
   persistent cough caused by gastroesophageal reflux. Jpn. 
   J. Thoracic Dis. 1993; 31: 1303-7 (in Japanese with an 
   English abstract). 
27 Fujimori K, Suzuki E, Arakawa M. Clinical features of 
   Japanese patients with chronic cough induced by gastro-
   esophageal reflux. Allergol. Int. 1997; 46 (in press).
